Press Releases 2018
Below you can access Liminal BioSciences press releases for 2018. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.
-
Prof. Simon Best appointed interim CEO of Prometic Life Sciences
Prometic announced today that it has named Prof. Simon Best as Interim Chief Executive Officer, effective immediately.
-
Press Releases 2021
Read More -
Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome
The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.
-
Prometic provides corporate update
This includes a significant reduction in the Corporation’s cash use in 2019, driven by significant growth in its bioseparation revenues & a reduction of anticipated R&D expenditures by up to $30m.
-
Prometic reports third quarter 2018 financial results and highlights
Implementation of cost control measures to significantly reduce operational burn and extend cash runway
-
Prometic closes its extension of debt maturities to 2024
Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024
-
Prometic to report its third quarter 2018 financial results and hold conference call / webcast
Prometic announced today that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close.
-
Prometic announces extension of debt maturities to 2024
As a result of the extension, the maturity dates of the Debt will be amended to September 2024, requiring no repayment of the sums borrowed until then.
-
Prometic announces second annual plasminogen deficiency awareness week
This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event
-
Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA
Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing
-
Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome
Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).
-
Prometic reports second quarter 2018 financial results and highlights
Prometic has advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
-
Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology
n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.
-
Prometic to report its second quarter 2018 financial results and hold conference call / webcast
Prometic announced today that it will report its financial results for the second quarter ended June 30, 2018 on Tuesday August 14, 2018 after market close.
-
Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).
-
Prometic conference call to present progress report on AGM corporate action plan
Prometic it will hold a conference call on Wednesday June 27, 2018 to report on its progress in implementing the updated corporate plan presented during its AGM on Wednesday May 9th 2018.
-
Prometic presents new data on NASH drug candidate PBI-4547
New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity.
-
Prometic presents new clinical data on PBI-4050 for the treatment of Idiopathic Pulmonary Fibrosis
Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity
-
Prometic reports its 2018 first quarter highlights and financial results
Clinical programs streamlined to manage costs for balance of 2018 and continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions
-
Prometic reports on its 2018 annual and special meeting of shareholders highlights
Prometic continued in 2017 its transition that has transformed the company into a biopharmaceutical company with two drug discovery platforms focusing on rare and orphan diseases.
-
Prometic reports positive clinical data from its intravenous immunoglobulin (IVIG) pivotal phase 3 trial
Prometic’s IVIG demonstrated comparable safety and efficacy data to existing commercial IVIG products without any significant drug related safety issues.
-
Loading More...